Topical administration of tranexamic acid in primary total hip and total knee arthroplasty.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 24238825.
- Also identified by DOI 10.1016/j.arth.2013.10.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Major blood loss is a known potential complication in total hip and total knee arthroplasty. We conducted a prospective, stratified, randomized, double-blind, placebo-controlled trial that evaluated 100 patients undergoing total knee or total hip arthroplasty to evaluate the effect on blood loss using the topical application of tranexamic acid. Participants received either 2 g of topical tranexamic acid or the equivalent volume of placebo into the joint prior to surgical closure. Tranexamic acid resulted in a lower mean maximum decline in postoperative hemoglobin levels when compared to placebo (P = 0.013). Patients in the tranexamic acid group demonstrated an improved but non-significant reduction in the units of blood transfused compared to placebo (P = 0.423). There was no clinically significant increase in complications in the tranexamic acid group, including no incidence of venous thromboembolism.
Medical subject headings
- Antifibrinolytic Agents
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- Blood Loss, Surgical
- Postoperative Hemorrhage
- Tranexamic Acid
Anatomy
- hip
- knee